Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) — The global liquid biopsy market, valued at US$3.65 billion in 2024, stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted valuation of US$7.05 billion by the end of the period. Driven by rising cancer incidence, accelerating adoption of precision medicine, and significant technological advancements, liquid biopsy is emerging as a cornerstone in early disease detection, oncology care, and personalized medicine.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Transforming Cancer Detection and Treatment
What is driving this surge? The growing global cancer burden is the primary catalyst. Liquid biopsy offers a minimally invasive, repeatable alternative to tissue biopsies—enabling clinicians to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers through a simple blood test. This provides oncologists with real-time insights into tumor dynamics, helping guide timely and accurate treatment decisions.
Why does it matter now? With cancer cases climbing worldwide, healthcare systems are under pressure to adopt faster, safer, and more cost-effective diagnostics. Liquid biopsy not only supports early detection but also allows physicians to track therapeutic resistance and adjust treatment strategies accordingly—improving outcomes and reducing overall costs.
Expanding Clinical Applications Beyond Oncology
Where is liquid biopsy making new inroads? Beyond cancer care, its applications are rapidly expanding into non-invasive prenatal testing and organ transplantation monitoring. In both fields, liquid biopsy provides actionable insights without the risks associated with invasive procedures.
How is technology reshaping the market? Innovations such as next-generation sequencing (NGS), digital PCR, and enhanced biomarker detection methods are improving the sensitivity, reliability, and clinical utility of liquid biopsy assays. These breakthroughs are making liquid biopsy an indispensable tool across a wider spectrum of healthcare settings.